Carmat Market Cap ($6.37 Million)
Market Cap & Net Worth: Carmat (ALCAR)
Carmat market cap. Carmat (PA:ALCAR) has a market capitalization of $6.37 Million (€5.44 Million) as of November 5, 2026. Listed on the PA stock exchange, this France-based company holds position #28011 globally and #495 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Carmat's stock price €0.10 by its total outstanding shares 64254002 (64.25 Million). Also see ALCAR cash generation efficiency for how efficiently the company converts equity into cash flow.
Carmat Market Cap History (2015–2026)
Carmat market cap history from 2015 to 2026. Data shows change from $2.98 Billion to $7.44 Million (-45.32% CAGR). Check latest Carmat stock price today for real-time trading data and today's change.
Index Memberships
Carmat is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC PME
CAPME
|
$39.53 Billion | 0.02% | #27 of 34 |
Weight: Carmat's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Carmat Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Carmat's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ALCAR shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
11.70x
Carmat's market cap is 11.70 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.98 Billion | $14.35K | -$17.55 Million | 207613.52x | N/A |
| 2016 | $2.09 Billion | $173.17K | -$22.98 Million | 12047.38x | N/A |
| 2017 | $1.57 Billion | $28.00K | -$29.23 Million | 56211.52x | N/A |
| 2018 | $1.71 Billion | $14.00K | -$41.73 Million | 121972.90x | N/A |
| 2019 | $1.40 Billion | $14.00K | -$42.65 Million | 100069.61x | N/A |
| 2020 | $2.06 Billion | $9.00K | -$36.96 Million | 228490.70x | N/A |
| 2021 | $1.48 Billion | $2.23 Million | -$61.87 Million | 663.41x | N/A |
| 2022 | $757.90 Million | $345.00K | -$53.68 Million | 2196.80x | N/A |
| 2023 | $486.85 Million | $2.85 Million | -$53.87 Million | 170.94x | N/A |
| 2024 | $81.88 Million | $7.00 Million | -$51.40 Million | 11.70x | N/A |
Competitor Companies of ALCAR by Market Capitalization
Companies near Carmat in the global market cap rankings as of November 5, 2026. Also see how large is Carmat's balance sheet for a full breakdown of the balance sheet.
Key companies related to Carmat by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #110 globally with a market cap of $190.23 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #204 globally with a market cap of $119.12 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #226 globally with a market cap of $109.30 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #239 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #110 | Abbott Laboratories | NYSE:ABT | $190.23 Billion | $109.40 |
| #204 | Stryker Corporation | NYSE:SYK | $119.12 Billion | $310.55 |
| #226 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $98.88 |
| #239 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Market Capitalization of Carmat (2015–2026)
Market capitalization of Carmat from 2015 to today. Between 2015 and today, Carmat's market cap moved from $2.98 Billion to $ 7.44 Million, with a yearly change of -45.32%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €7.44 Million | 0.00% |
| 2025 | €7.44 Million | -90.92% |
| 2024 | €81.88 Million | -83.18% |
| 2023 | €486.85 Million | -35.76% |
| 2022 | €757.90 Million | -48.75% |
| 2021 | €1.48 Billion | -28.09% |
| 2020 | €2.06 Billion | +46.78% |
| 2019 | €1.40 Billion | -17.96% |
| 2018 | €1.71 Billion | +8.49% |
| 2017 | €1.57 Billion | -24.56% |
| 2016 | €2.09 Billion | -29.98% |
| 2015 | €2.98 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Carmat was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.37 Million USD |
| MoneyControl | $6.37 Million USD |
| MarketWatch | $6.37 Million USD |
| marketcap.company | $6.37 Million USD |
| Reuters | $6.37 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Carmat
Carmat SA designs and develops total artificial heart for patients with advanced heart failure in France and internationally. The company offers Aeson, an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The company was incorporated in 2008 and is headquartered in Vélizy-Villacoublay, France.